Rhabdomyolysis Associated with Cerivastatin-Gemfibrozil Combination Therapy: 1 case.
- Author:
Sin Chul KIM
1
;
Myoung Chun KIM
;
Young Gwan KO
Author Information
1. Department of Emergency Medicine, College of Medicine, Kyung Hee University, Korea.
- Publication Type:Original Article
- Keywords:
Cerivastatin;
Gemfibrozil;
Rhabdomyolysis
- MeSH:
Cytochrome P-450 Enzyme System;
Dyslipidemias;
Female;
Gemfibrozil;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Isoenzymes;
Metabolic Networks and Pathways;
Middle Aged;
Muscular Diseases;
Myositis;
Oxidoreductases;
Rhabdomyolysis*
- From:Journal of the Korean Society of Emergency Medicine
2001;12(4):565-569
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Most currently available statins are associated with an increase with risk of myositis, including rhabdomyolysis. Myopathy is believed to be caused by interference in the cytochrome P450 3A4 enzyme system, which results in a marked increase in reductase activity. Cerivastatin, a new synthetic HMG-CoA reductase inhibitor, is a safe, well-tolerated effective drug for the treatment of patients with dyslipidemia. The drug is metabolized by the cytochrome P450 3A4 and cytochrome P450 2C8 hepatic isoenzymes. Because of this dual metabolic pathway, it has been suggested that cerivastatin is less subject to drug-todrug interactions. We describe a 60-year-old woman with rhabdomyolysis and localized myositis, after she had taken cerivastatin(lipobay, 0.3 mg/day) and gemfibrozil(lopid, 500 mg/day) for 1month.
